← stocks-llm New chat

ANIKA THERAPEUTICS INC (ANIK) — insider trading

Health Care · NASDAQ

ANIKA THERAPEUTICS INC (ANIK) has 31 reported SEC Form 4 insider transactions in our data, including 2 open-market purchases among the most recent 31 (latest 2026-06-18).

Recent Form 4 transactions

DateInsiderRoleTypeSharesPriceValueFiling
2026-06-18 CONLEY SHERYL L Director Grant / award / vesting 10,402 $0.00 $0 Form 4
2026-06-18 Capper Joseph H Director Grant / award / vesting 10,402 $0.00 $0 Form 4
2026-06-18 Richard Stephen Director Grant / award / vesting 10,402 $0.00 $0 Form 4
2026-06-18 HENNEMAN JOHN B III Director Grant / award / vesting 10,402 $0.00 $0 Form 4
2026-06-18 Fischetti Gary P Director Grant / award / vesting 10,402 $0.00 $0 Form 4
2026-06-03 Griffin Stephen D. Director, Officer (President and CEO) Option exercise / conversion (derivative) 12,840 $0.00 $0 Form 4
2026-06-03 Griffin Stephen D. Director, Officer (President and CEO) Shares withheld for taxes / exercise cost 3,769 $14.41 $54.3K Form 4
2026-06-03 Griffin Stephen D. Director, Officer (President and CEO) Option exercise / conversion 12,840 Form 4
2026-05-01 HENNEMAN JOHN B III Director Open-market purchase 5,000 $14.66 $73.3K Form 4
2026-04-30 Griffin Stephen D. Director, Officer (President and CEO) Open-market purchase 12,200 $12.29 $149.9K Form 4
2026-03-19 McLeod Ian Officer (SVP, CAO & Treasurer) Grant / award / vesting (derivative) 17,663 $0.00 $0 Form 4
2026-03-19 McLeod Ian Officer (SVP, CAO & Treasurer) Grant / award / vesting (derivative) 11,194 $0.00 $0 Form 4
2026-03-19 McLeod Ian Officer (SVP, CAO & Treasurer) Grant / award / vesting (derivative) 13,097 $0.00 $0 Form 4
2026-03-15 Blanchard Cheryl R Director Option exercise / conversion (derivative) 25,131 $0.00 $0 Form 4
2026-03-15 Blanchard Cheryl R Director Shares withheld for taxes / exercise cost 12,104 $14.20 $171.9K Form 4
2026-03-15 Blanchard Cheryl R Director Option exercise / conversion 25,131 Form 4
2026-03-15 Colleran David Officer (EVP, General Counsel, Corp Sec) Option exercise / conversion (derivative) 6,449 $0.00 $0 Form 4
2026-03-15 Colleran David Officer (EVP, General Counsel, Corp Sec) Shares withheld for taxes / exercise cost 1,893 $14.20 $26.9K Form 4
2026-03-15 Colleran David Officer (EVP, General Counsel, Corp Sec) Option exercise / conversion 6,449 Form 4
2026-03-14 Blanchard Cheryl R Director Option exercise / conversion (derivative) 24,519 $0.00 $0 Form 4
2026-03-14 Blanchard Cheryl R Director Shares withheld for taxes / exercise cost 14,728 $14.20 $209.1K Form 4
2026-03-14 Blanchard Cheryl R Director Grant / award / vesting 24,520 $0.00 $0 Form 4
2026-03-14 Blanchard Cheryl R Director Option exercise / conversion 24,519 Form 4
2026-03-14 Griffin Stephen D. Director, Officer (President and CEO) Option exercise / conversion (derivative) 12,824 $0.00 $0 Form 4
2026-03-14 Griffin Stephen D. Director, Officer (President and CEO) Shares withheld for taxes / exercise cost 5,944 $14.20 $84.4K Form 4
2026-03-14 Griffin Stephen D. Director, Officer (President and CEO) Grant / award / vesting 6,412 $0.00 $0 Form 4
2026-03-14 Griffin Stephen D. Director, Officer (President and CEO) Option exercise / conversion 12,824 Form 4
2026-03-14 Colleran David Officer (EVP, General Counsel, Corp Sec) Option exercise / conversion (derivative) 9,388 $0.00 $0 Form 4
2026-03-14 Colleran David Officer (EVP, General Counsel, Corp Sec) Shares withheld for taxes / exercise cost 4,168 $14.20 $59.2K Form 4
2026-03-14 Colleran David Officer (EVP, General Counsel, Corp Sec) Grant / award / vesting 4,694 $0.00 $0 Form 4
2026-03-14 Colleran David Officer (EVP, General Counsel, Corp Sec) Option exercise / conversion 9,388 Form 4

Ask the chat about ANIK's insider activity →

Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.

Source: SEC EDGAR Form 3/4/5. See the full company profile: ANIKA THERAPEUTICS INC (ANIK).

Last updated 2026-06-18 (most recent filing date).

Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.